SAN DIEGO, Calif., July 7, 2026
Nucleus Biologics has launched CRAIC™ Formulation Finder, a new large language model (LLM)-powered assistant designed to help researchers rapidly identify, develop, and optimize cell culture media and buffer formulations for advanced cell therapy applications. Integrated into the company’s NB-Lux™ AI digital ecosystem, the new platform enables scientists to describe their desired biological outcomes using natural language, eliminating the need for extensive literature reviews, manual formulation comparisons, or lengthy trial-and-error experimentation. By analyzing factors including cell type, desired phenotype, process requirements, manufacturing constraints, and performance objectives, CRAIC™ generates customized formulation recommendations within minutes. Researchers can immediately evaluate feasibility, request pricing, customize formulations, and place manufacturing orders directly through the platform, significantly reducing development timelines and supporting faster progression from laboratory research to clinical manufacturing.
AI-Driven Workflow Connects Discovery with Manufacturing
Unlike general-purpose artificial intelligence platforms, CRAIC™ Formulation Finder has been specifically developed for cell culture media and buffer formulation, combining advanced LLM technology with Nucleus Biologics’ proprietary formulation expertise and extensive manufacturing database. The platform creates a seamless digital workflow that connects formulation design with customization, quotation, manufacturing, and product delivery through NB-Lux™ AI. Scientists can optimize formulations according to experimental goals and manufacturing requirements while maintaining compatibility with scalable production processes. According to the company, the integrated system enables researchers to develop, optimize, and begin testing new formulations within approximately 30 days, helping reduce development bottlenecks in cell and gene therapy, regenerative medicine, and other advanced biologics programs. By combining scientific knowledge with manufacturing intelligence, the platform is intended to improve formulation quality while accelerating research and development activities.
Purpose-Built AI Enhances Cell Therapy Research Efficiency
David Sheehan, Founder, President, and Chief Executive Officer of Nucleus Biologics, said the launch represents a significant milestone in applying artificial intelligence to life science research and biomanufacturing. He noted that modern LLMs now enable near real-time optimization of media formulations by incorporating metabolomic and genomic attributes, giving scientists greater control over developing optimized media tailored to specific biological systems. Sheehan described the technology as an opportunity for researchers to leverage decades of published scientific knowledge alongside the company’s manufacturing expertise to accelerate innovation and reduce the time required to advance therapies toward the clinic. He added that the quality of formulation recommendations is expected to improve continuously as the platform evolves and incorporates additional scientific data and manufacturing insights, further enhancing research productivity across the biotechnology industry.
Advertisement
TaiMed Expands Global HIV Strategy Following Regulatory Success
The introduction of CRAIC™ Formulation Finder further expands Nucleus Biologics’ integrated digital ecosystem designed to streamline media and buffer development, manufacturing, and supply chain management for biotechnology organizations. The company provides custom media and buffer solutions, laboratory technologies, and GMP and Excipient GMP-compliant manufacturing services aimed at supporting advanced therapies from early discovery through commercial production. By integrating AI-assisted formulation design with manufacturing and ordering capabilities, NB-Lux™ AI enables researchers to transition efficiently from concept to production within a single platform. CRAIC™ Formulation Finder is now available to users through the NB-Lux™ AI platform and is expected to support organizations developing cell therapies, gene therapies, biologics, and regenerative medicine products, helping accelerate innovation while improving formulation accuracy, scalability, and manufacturing readiness across the life sciences sector.
Source: Nucleus Biologics, press release
